Can self-reported data from patients be trusted? Depends on the outcome

As the saying goes, You can’t always believe what you hear. But when it comes to patients self-reporting health care utilization, just how accurate can people be? A study, published July 30 in the Journal of Medical Internet Research, examined patients’ abilities to recall complications in the 90 days after orthopedic procedures through an automated online patient engagement survey.

The researchers—led by Benjamin I. Roser, MD, PhD, with Kaiser Permanente in Santa Clara, California—conducted the multicenter observational study across 10 orthopedic practices in California and Nevada, including 371 individuals who underwent procedures between March 1, 2015, and July 1, 2016. The cohort averaged 56.5 years in age, and 48.8 percent were female.

Roser and colleagues found:

  • Patients were found to have accuracy of self-report characterized by a kappa of 0.80 and agreement of 0.99 and a kappa of 1.00 and agreement of 1.00 for 90-day hospital admissions and pulmonary embolism, respectively.
  • Accuracy of self-report of 90-day emergency room/urgent care visits and of surgical site infection were characterized by a kappa of 0.45 and agreement of 0.96 and a kappa of 0.53 and agreement of 0.97, respectively.
  • Accuracy for other complications such as deep vein thrombosis, hemorrhage, severe constipation and fracture/dislocation was lower, influenced by low event prevalence rates within the sample.

“[T]his investigation suggests the potential that engaging patients in self-report through such survey modalities may offer for the timely and accurate measurement of matters germane to health care organizations engaged in quality improvement efforts post discharge,” wrote the authors.

Improvement can be dependent on an institution’s understanding of the value of self-reported data from patients.

“If quality improvement is a goal, and readmissions and post-encounter complications represent the last mile in the healthcare quality chain, could patients become active participants by providing accurate and timely information about these outcomes back to healthcare organizations?” said Roser et al.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.